ObjectiveTo systemically evaluate the effect of transplant children carrying cytochrome P450 family 3 subfamily A member 5*1 (CYP3A5*1) on tacrolimus administration dosage, plasma concentration, concentration-to-dose ratio (C/D) value. MethodsLiterature of effect of transplant children carrying CYP3A5*1 (CYP3A5*1/*1 or CYP3A5*1/*3) on tacrolimus administration dosage, plasma concentration, C/D value were enrolled through retrieving the PubMed, Scopus, ISI Web of Science, ProQuest, China National Knowledge Infrastructure, VIP, Wanfang Data Knowledge Service Platform. After evaluating literature quality and extracting data, the RevMan 5.3 software was used for Meta-analysis. ResultsA total of 13 literature was enrolled for Meta-analysis. The results of Meta analysis revealed that on the first, second, third, sixth, and twelfth month after transplant, there was statistically significant difference in tacrolimus administration dosage between children carrying CYP3A5*1 and non-carriers (P＜0.05), therein, the carriers obtained a larger tacrolimus administration dosage; moreover, on the first and second week, as well as on the first, second, and sixth month after transplant, tacrolimus plasma concentration of children carrying CYP3A5*1 was lower than that of children without carrying CYP3A5*1 (P＜0.05); in addition, on the first and second week, and on the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth month after transplant, the C/D value of tacrolimus of children carrying CYP3A5*1 was lower than that of non-carriers (P＜0.05). ConclusionThere are significant differences in tacrolimus administration dosage, plasma concentration, and C/D value between transplant children carrying CYP3A5*1 and non-carriers, therein, the carriers require a larger dose of tacrolimus. Detection of CYP3A gene polymorphisms before administration helps to predict the dose requirement for an individual.

无